Company
Headquarters: Suwanee, GA, United States
Employees: 27
CEO: Ms. Kathy Lee-Sepsick
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $193.76 B |
| EssilorLuxottica SA | $128.90 B |
| Becton, Dickinson and Company | $50.81 B |
| Alcon Inc. | $44.33 B |
| HOYA Corp | $40.30 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Femasys, Inc. has the following listings and related stock indices.
Stock: NASDAQ: FEMY wb_incandescent